September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Reduction in Subfoveal Choroidal Thickness after Thalidomide Treatment in Patients with POEMS Syndrome
Author Affiliations & Notes
  • Hirotaka Yokouchi
    Ophthalmology, Chiba Univ Graduate School of Med, Chiba, Chiba, Japan
  • Takayuki Baba
    Ophthalmology, Chiba Univ Graduate School of Med, Chiba, Chiba, Japan
  • Toshiyuki Oshitari
    Ophthalmology, Chiba Univ Graduate School of Med, Chiba, Chiba, Japan
  • Shuichi Yamamoto
    Ophthalmology, Chiba Univ Graduate School of Med, Chiba, Chiba, Japan
  • Footnotes
    Commercial Relationships   Hirotaka Yokouchi, None; Takayuki Baba, None; Toshiyuki Oshitari, None; Shuichi Yamamoto, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 4568. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Hirotaka Yokouchi, Takayuki Baba, Toshiyuki Oshitari, Shuichi Yamamoto; Reduction in Subfoveal Choroidal Thickness after Thalidomide Treatment in Patients with POEMS Syndrome. Invest. Ophthalmol. Vis. Sci. 2016;57(12):4568.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To determine the changes in the subfoveal choroidal thickness (CT), the foveal thickness (FT), and the serum level of vascular endothelial growth factor (VEGF) after thalidomide treatment in patients with the polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome.

Methods : This was retrospective, observational case series. We studied 22 eyes of 11 treatment-naïve patients with the POEMS syndrome at the Chiba University Hospital from January 2013 through May 2015. The subfoveal CT and FT were determined by enhanced depth imaging optical coherence tomography (EDI-OCT) at the baseline and at 6 months after the thalidomide treatment. The serum level of VEGF was also determined by enzyme-linked immunosorbent assays (ELISAs) at the baseline and at 6 months after the thalidomide treatment. The correlations between the serum level of VEGF and the subfoveal CT or the FT at the baseline and at 6 months after thalidomide treatment were determined.

Results : At the baseline, the mean subfoveal CT was 455.7 ± 56.0 µm (right eye, 457.8 ± 53.2 µm; left eye, 453.7 ± 61.3 µm), the mean FT was 245.9 ± 50.9 µm (right eye, 255.7 ± 64.0 µm; left eye, 236.1 ± 33.6 µm), and the mean serum level of VEGF was 8103 ± 3617 pg/ml. At 6 months after thalidomide treatment, the mean serum level of VEGF significantly decreased to 1556 ± 1751 pg/ml (P<0.001) and the subfoveal CT significantly decreased along with an improvement in the serum level of VEGF to 315.3 ± 82.2 µm (right eye, 319.2 ± 86.9 µm, P<0.0001; left eye, 311.3 ± 81.2 µm, P<0.0001). On the other hand, the mean FT did not significantly change from the baseline (both eyes, 227.5 ± 34.4µm, P>0.05; right eye, 227.4 ± 34.2 µm, P>0.05; left eye, 227.6 ± 36.2 µm, P>0.05). At 6 months after treatment, the change in subfoveal CT from baseline in all eyes was significantly and linearly related to the change in the serum levels of VEGF from baseline (r=0.66, P<0.001) but the change in FT from baseline in all eyes was not significantly related to the change in the serum levels of VEGF.

Conclusions : The decrease in the subfoveal CT along with the decrease in the serum level of VEGF suggests that serum levels of VEGF might influence the choroidal thickness in patients with POEMS syndrome.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×